Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma
Lars P. Jordheim,
Vincent Ribrag,
Hervé Ghesquieres,
Sophie Pallardy,
Richard Delarue,
Hervé Tilly,
Corinne Haioun,
Fabrice Jardin,
Delphine Demangel,
Gilles A. Salles,
Charles Dumontet
Affiliations
Lars P. Jordheim
Anticancer Antibody Team, INSERM U1052, CNRS UMR 5286, Cancer Research Center of Lyon, France;Hospices Civils de Lyon, France;ProfileXpert, Lyon, France
Vincent Ribrag
Institut Gustave Roussy, Villejuif, France
Hervé Ghesquieres
Hematology, Centre Léon Bérard, UMR 5239 CNRS, Lyon, France
Sophie Pallardy
GELA-RC, Hospices Civils de Lyon, Pierre Bénite, France
Richard Delarue
Hematology, Necker Hospital, Paris, France
Hervé Tilly
Centre Henri Becquerel, Rouen, France
Corinne Haioun
Hematology, Hôpital Henri Mondor, Créteil, France
Fabrice Jardin
Hematology, INSERM U918, Centre Henri Becquerel, Rouen, France
Delphine Demangel
Hospices Civils de Lyon, France;ProfileXpert, Lyon, France
Gilles A. Salles
Hospices Civils de Lyon, Centre Hospitalier Universitaire Lyon-Sud, Hématologie, Université Lyon 1, UMR 5239 CNRS, France
Charles Dumontet
Anticancer Antibody Team, INSERM U1052, CNRS UMR 5286, Cancer Research Center of Lyon, France;Hospices Civils de Lyon, France;ProfileXpert, Lyon, France;Laboratory of Hematology, Hospices Civils de Lyon, Pierre-Bénite, France
